{"entity":{"id":"tairx","kind":"company","name":"TaiRx","aka":["台睿生物科技"],"tldr":"TaiRx is a Taiwan-based biotechnology company that leads 3 cancer trials in OnCo, testing the oral anti-cancer agent CVM-1118 (foslinanib) in hepatocellular carcinoma, neuroendocrine tumours, pancreatic ductal adenocarcinoma and advanced solid tumours.","summary":"TaiRx is a Taipei-based new drug development company. Its lead candidate CVM-1118 (foslinanib) is an oral anti-cancer agent in phase 2 for neuroendocrine tumours and hepatocellular carcinoma, and it also markets Zelnite, an injectable selenium product approved in Taiwan. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07521852 (phase 2, A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and...), NCT05257590 (phase 2, CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma) and NCT03600233 (phase 2, Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.trx.com.tw"},{"label":"ClinicalTrials.gov: trials led by TaiRx","url":"https://clinicaltrials.gov/search?lead=TaiRx%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07521852","nct05257590","nct03600233"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.trx.com.tw","ticker":"TPEx:6580","founded":2011,"stage":"public","investors":[],"funding":[]},"route":"/companies/tairx/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"trial":[{"id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/"},{"id":"nct05257590","kind":"trial","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","route":"/trials/nct05257590/"},{"id":"nct03600233","kind":"trial","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","route":"/trials/nct03600233/"}]}}